• Release date: 12/2/2025

• Expiration date: 12/2/2028

• Estimated time to complete activity: 13.5 hours

• Jointly provided by Partners for Advancing Clinical Education (Partners) and CME Science

Educational Objectives

This course provides a clinical perspective of PET/CT imaging and the emerging use of Theranostic agents within Nuclear Medicine. A broad perspective on the economic, clinical, and academic aspects of the latest trends in PET/CT imaging and Nuclear Medicine therapy will be presented.

At the conclusion of this course, participants will be able to:

  • Describe new developments in the merger of diagnostic and therapeutic radioligands for PET/CT imaging and therapy with specific focus on DOTA, PSMA, and PRRT
  • Describe the logistis of bringing these new diagnostic and therapeutic technologies to clinical practice
  • Identify the key clinical indications for new emerging tracers for Neuroendocrine Tumor and Prostate cancer using somatostatin receptor and PSMA PET/CT imaging
  • Review and discuss the standard-of-care clinical application and advanced interpretation of FDG PET/CT

With the recent approval by CMS Medicare for DOTATATE (NETSPOT) PET/CT and the rapid international adoption of targeted Lu-177 based therapies for neuroendocrine and prostate cancers, it is clear that Nuclear Medicine and PET/CT are entering into a new era. New diagnostic and therapeutic agents with remarkable sensitivity and specificity are revolutionizing Nuclear Medicine and Oncology. This course will highlight the latest targeted imaging agents for neuroendocrine and prostate cancers (Ga-68 DOTATATE and Ga-68 PSMA PET/CT) as well as review important core concepts in PET/CT imaging and therapeutic Nuclear Medicine.

Faculty

Phillip Kuo, MD, PhD, FACR

Professor of Medical Imaging, Biomedical Engineering, and Medicine

University of Arizona, Tucson, Arizona

Andrew Quon, MD

Professor

David Geffen School of Medicine at UCLA

Don C. Yoo, MD

Professor of Diagnostic Imaging, Clinician Educator

The Warren Alpert Medical School of Brown University

Director of Nuclear Medicine, The Miriam Hospital

Course Curriculum

Advanced PET Imaging 2026

Advanced PET Imaging 2026

  1. Introduction to Theranostics - Phillip Kuo, MD
  2. Update on Radioiodine Treatment for Thyroid Cancer and the Role of PET/CT - Don C. Yoo, MD
  3. Importance of Patient Preparation for PET/CT - Don C. Yoo, MD
  4. PET/CT in Head and Neck Cancer - Don C. Yoo, MD
  5. Dopamine Transporter Imaging of Parkinsonian Syndromes - Phillip Kuo, MD
  6. Case-Based Review of PET/CT for Amyloid Imaging. - Phillip Kuo, MD
  7. PSMA PET Optimizing Therapy Response Assessment - Don C. Yoo, MD
  8. Update on Nuclear Medicine for Infection and Inflammation - Don C. Yoo, MD
  9. Amyloid and Tau Brain PET Rebooted - The New Era of Neurotheranostics for Dementia - Phillip Kuo, MD
  10. Understanding the Role of PSMA-PET in Selecting Patients for PSMA-Targeted Therapy - Phillip Kuo, MD
  11. Challenging and Instructive Abdomen and Pelvis PET/CT Review - Don C. Yoo, MD
  12. Pearls and Pitfalls for FDG-PET - Phillip Kuo, MD
  13. Challenging and Instructive Chest PET/CT Review - Don. C. Yoo, MD
  14. PET Imaging for the Differential Diagnosis of Dementia - Phillip Kuo, MD
  15. PET/CT Case Conference - Andrew Quon, MD
  16. Prostate Cancer PET Imaging - Andrew Quon, MD
  17. Nuclear Medicine Theranostics- From PET Scans to Therapy - Andrew Quon, MD
  18. IMPORTANT: HOW TO CLAIM YOUR CREDIT

Pricing

$1,399.00 USD
Advanced PET Imaging 2026
13.5 AMA PRA Category 1 Credit(s)™

Enroll Now

Refund Policy: Cancellation and refund requests must be made within 24 hours of purchase. Within the first 24 hours you may cancel and be refunded the full amount of the purchase , less a $100.00 administrative fee. After 24 hours no refunds will be allowed.

Please note: If you have applied for CME credit during this period “NO” refunds will be available.

 

Important Notice Regarding Copyright and Usage

All materials purchased from CME Science are protected by copyright and are for the sole personal use of the purchaser.

 

Distributing, forwarding, transferring, reproducing, or reselling these educational materials in any way is strictly prohibited and constitutes copyright infringement. This includes, but is not limited to, sharing them with others, posting them online, or incorporating them into other products or services.

 

Your license to access these materials is non-transferable and applies only to you, the original purchaser.

 

We reserve the right to terminate or restrict your access to our service, without prior notice, if we find any violation of these terms and conditions.

JA

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Partners for Advancing Clinical Education (Partners) and CME Science. Partners for Advancing Clinical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Credit Designation

Partners for Advancing Clinical Education (Partners) designates this enduring material for a maximum of 13.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Faculty and Disclosure of Conflicts of Interest

Partners for Advancing Clinical Education (Partners) requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated according to Partners policies. Others involved in the planning of this activity have no relevant financial relationships.

  • Dr. Phillip Kuo, faculty for this activity, Consultant and/or speaker for Amgen, Bayer, Blue Earth Diagnostics, Chimerix, Eisai, Fusion Pharma, General Electric Healthcare, Invicro, Novartis, Radionetics, and UroToday. He is a recipient of research grants from Blue Earth Diagnostics and General Electric Healthcare.
  • Dr. Andrew Quon, faculty for this activity, has no relevant financial relationships.
  • Dr. Don C. Yoo, faculty for this activity, Consultant, Invicro LLC.

Media

Internet

Computer System Requirements

Any internet accessible device.

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

For additional information about the accreditation of this activity, please visit https://partnersed.com